Xiamen Amoytop Biotech Co., Ltd. is an innovative biopharmaceutical company in China, specialized in R&D, manufacturing and marketing of regular and long-acting recombinant protein drugs. Focusing on the R&D of immune-related cytokine medicines, Amoytop Biotech is committed to becoming a leader in solving cytokine medicine-based systemic immune problems, providing better solutions for major diseases (such as viral hepatitis, malignant tumors) and immunotherapy. Currently, Amoytop Biotech is specially focusing on CHB (chronic hepatitis B) treatment aiming to achieve breakthroughs in clinical cure of CHB.
Targeting major diseases and immunotherapy fields, Amoytop Biotech has built an innovation platform covering the expression, long-acting modification and industrialization of various protein drugs, and owned the innovation ability in fundamental research, pilot-scale research, clinical study and industrialization research. Now,and been awarded as a national innovation-oriented enterprise which has advantages in national intellectual property. Keeping the global market in mind, Amoytop Biotech spares every effort to explore international markets based on the domestic market. Up to now, Amoytop Biotech has marketed its products in South-East Asia, South America and CIS area. Through technical innovation, scientific management and product industrialization, Amoytop Biotech aims to gradually become a leading international biopharmaceutical company in China.
National innovation team in priority area
Launched drug products
National Major Scientific and Technological Special Projects for Significant New Drug Development
After 14-year development, the long-acting interferon drug product of Amoytop Biotech, Pegberon® (pegylated interferon alfa-2b), national class-1 new drug, was approved in China in 2016. Pegberon is the first 40kD Y-shape branched PEG modified interferon alfa-2b injection in the world, with special structure in complete patent protection, has broken the monopoly of foreign products in treatment of viral hepatitis, and awarded with “2016 Top 10 China Medicinal Biotech Progress” by China Medicinal Biotechnology Association.
Recently, with the idea of “clinical cure” in chronic hepatitis B treatment filed has been gradually recognized by hepatitis specialists and clinicians, Amoytop Biotech has supported/conducted a series of research projects aiming to improve CHB clinical cure level, including CHB clinical cure projects listed in the National Major Scientific and Technological Special Projects during the “13th Five-year Plan” period, exploratory researches on the application and optimization of chronic hepatitis B clinical cure, and relevant confirmatory clinical trials. Through continuous exploration and accumulation, Amoytop Biotech is devoted to be the leader in CHB clinical cure field based on pegylated interferon alfa-2b.
Devoted to Constant Innovation in Biopharmaceutical Field for a Better and Healthier Life for Human
To be a Leading International Biopharmaceutical Company in China
Founded Amoytop Biotech
Launched TOPLEUCON® (rHuGM-CSF), the first China-made GM-CSF
Launched TOPNEUTER® (rHuG-CSF)
Founded wholly-owned research institute,“Xiamen Biosteed Gene Transformation Tech. Co. ,Ltd.”
Undertook the Demonstration Project of Industrialization and Internationalization of Genetically Engineered Protein Drugs for National Development and Reform Committee, China
Launched TOPMEGA® (rHuIL-11)
Established postdoctoral research station
Approved as“National-Local Joint Research Center”
Approved as“National Torch Program Key High-Tech Enterprises”
Approved as “National Innovation Team in Priority Fields” by Ministry of Science and Technology
Launched PEGBERON® (Peginterferon alfa-2b),national class 1 new drug
Listed on SSE STAR Market (Sci-tech innovation board, Shanghai Stock Exchange), the first biomedical stock from Fujian Province
Postdoctoral research station
National Innovation-Oriented Enterprise
National-Local Joint Research Center
Key High-Tech Enterprises of National Torch Program
China National Accreditation Service for Conformity Assessment (CNAS) certificate
Tel：86 592 6889105/108
Email： firstname.lastname@example.org / email@example.com
Add：No. 330 Wengjiao Road, Haicang, Xiamen, Fujian, China
Adverse Events Tel：86-592-6889111
Adverse Events Email：firstname.lastname@example.org